SRNE - Sorrento gets dosing underway in mid-stage COVIDROPS COVID-19 study

Sorrento Therapeutics (SRNE) announces that COVID-19 patients have been dosed in the company's Phase 2 efficacy trial of COVIDROPS.About 350 outpatients with COVID-19 who are asymptomatic or have mild symptoms will be enrolled in the large double-blind, randomized trial evaluating COVIDROPS doses of 10 mg or 20 mg against placebo.COVIDROPS is administered as a simple intranasal instillation into each nostril to recently infected subjects.The neutralizing antibody drug is highly active against the original SARS-CoV-2 virus, as well as the India/Delta and UK/Alpha variants currently prevalent in the UK and US, the company said.Sorrento had announced the formation a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico, earlier this week.

For further details see:

Sorrento gets dosing underway in mid-stage COVIDROPS COVID-19 study